Cell engineering

Kytopen Names Michael Chiu, Ph.D., as Chief Executive Officer

Retrieved on: 
Monday, August 7, 2023
University, Sigma-Aldrich, AUC, Marketing, Biotechnology, Innovation system, Merck Group, MIT, Patient, Growth, Teradyne, Cell engineering, Sloan Fellows, Pharmaceutical industry

CAMBRIDGE, Mass., Aug. 7, 2023 /PRNewswire/ -- Kytopen, a biotechnology company that develops and markets advanced cell engineering solutions, today announced the appointment of Michael Chiu, Ph.D., as Chief Executive Officer. An entrepreneurial leader with extensive experience in building and commercializing new technologies, he brings to Kytopen a proven track record in fundraising, product development, and marketing launches. Dr. Chiu succeeds Paulo A. Garcia, Ph.D., one of the company's co-founders, who will continue as an advisor.

Key Points: 
  • CAMBRIDGE, Mass., Aug. 7, 2023 /PRNewswire/ -- Kytopen, a biotechnology company that develops and markets advanced cell engineering solutions, today announced the appointment of Michael Chiu, Ph.D., as Chief Executive Officer.
  • Dr. Chiu joins Kytopen at the time of its accelerated roll-out of the Flowfect® technology to high-profile academic medical centers in the U.S.
  • Prior to this, he was the Chief Executive Officer of Erbi Biosystems, Inc., which was acquired by Merck KGaA, Darmstadt Germany (MilliporeSigma in US), last year.
  • Earlier in his career, he was a chief technology officer and senior executive with several high-tech companies, including Automation Engineering Inc. (acquired by Mycronic AB), Trophos Energy, and Teradyne.

AI+ Media Development Platform AlfaOPA™ Officially Launched

Retrieved on: 
Friday, August 4, 2023
Immortalised cell line, Drug development, Medium (website), Futures studies, CMC, Suzhou International Expo Center, Multimedia, GBB, Pleasure, AI, Cell engineering, Video game

At the summit, Great Bay Bio announced the official launch of its self-developed AI-enabled, no-screening culture media development platform, AlfaOPA™.

Key Points: 
  • At the summit, Great Bay Bio announced the official launch of its self-developed AI-enabled, no-screening culture media development platform, AlfaOPA™.
  • The platform innovatively integrates AI to optimize culture media, replacing the blind screening process in traditional culture media development.
  • The culture media development work can be completed in a single step by adding these to the existing culture media.
  • The AlfaOPA™ platform uses AI technology to precisely optimize customers' existing culture media, achieving high-quality culture media optimization in one step.

Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Thursday, August 3, 2023
NTLA, Intellia Therapeutics, Retirement, Investigational New Drug, Patient, Ventilator-associated lung injury, Cardiomyopathy, Cell engineering, Disease, Tissue, Gene editing, Research, European Academy of Allergy and Clinical Immunology, NK, AATD, Liver, FDA, IND, D, DNA, SERPINA1, HAE, ATM, Therapy, CRISPR, Liver disease, KLKB1, CTA, EAACI, TTR, ATTR, A1AT, Physician, Amyloidosis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Female, Pharmaceutical industry, Medical imaging, Fine chemical, Rare-earth element, Vaccine, Video game

The Company plans to present additional data from the ATTRv-PN arm of the Phase 1 study by year-end 2023.

Key Points: 
  • The Company plans to present additional data from the ATTRv-PN arm of the Phase 1 study by year-end 2023.
  • Collaboration Revenue: Collaboration revenue decreased by $0.4 million to $13.6 million during the second quarter of 2023, compared to $14.0 million during the second quarter of 2022.
  • G&A Expenses: General and administrative expenses increased by $8.5 million to $30.7 million during the second quarter of 2023, compared to $22.1 million during the second quarter of 2022.
  • Net Loss: The Company’s net loss was $123.7 million for the second quarter of 2023, compared to $100.7 million during the second quarter of 2022.

MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients

Retrieved on: 
Tuesday, August 1, 2023
Tissue, LSE, DNA, Partnership, Gene editing, Patient, Prime editing, Cell engineering, DSM-IV codes, Pharmaceutical industry, Vaccine

Under the terms of the agreement, Prime Medicine obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.

Key Points: 
  • Under the terms of the agreement, Prime Medicine obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.
  • “We are pleased to partner with Prime Medicine and support their breakthrough gene editing technology,” said Doug Doerfler, President and CEO of MaxCyte.
  • The Company is leveraging its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated, one-time, potentially curative genetic therapies.
  • Prime Medicine is MaxCyte’s 23rd strategic partnership overall, each of which generates pre-commercial milestone revenue and the vast majority of which include sales-based payments.

GenScript to Host Third Annual Gene & Cell Engineering Virtual Summit

Retrieved on: 
Thursday, July 20, 2023
CRISPR, Biotechnology, University, Genetic engineering, Gene editing, GenScript Biotech, Artificial gene synthesis, Cancer, Head, UCSD, Research, Akwa Ibom State Association of Nigeria, USA Inc., Autoimmunity, EDT, Editas Medicine, Transplant, Discovery, Human, Berlin Center, Engineering, Disease, Cell, Drug discovery, Lymphocyte, Cell engineering, UCLA, University of Delaware, Summit, Synthetic biology, Fine chemical, Vaccine, Medical device

PISCATAWAY, N.J., July 20, 2023 /PRNewswire/ -- GenScript USA Inc., the world's leading life-science research tools and services provider, announced its third annual GenScript Gene & Cell Engineering Virtual Summit, which will feature in-depth discussions and research presentations on the crucial gene-synthesis and cell-editing technologies that are transforming scientific and biomedical research today. 

Key Points: 
  • This free Summit will be held on July 26, 2023, from 11 a.m. to 6 p.m. EDT.
  • "As a leader in gene synthesis and gene editing technologies, GenScript has been fortunate to work with many pioneering scientists in cell and gene engineering," said Ray Chen, Ph.D., president of GenScript Life Science Group.
  • The summit showcases the role of genetic engineering in revolutionizing life-science research, advancing gene and cell therapies, and enabling the efficient development of invaluable biotherapeutics for various human diseases.
  • Dr. Yongli Shan, associate director of discovery biology at Vicinitas Therapeutics — Advancing protein stabilization therapeutic development and DUBTAC drug discovery through gene and cell engineering.

GenScript Biotech Corporation Presents the 3rd Annual Gene and Cell Engineering Summit

Retrieved on: 
Wednesday, July 19, 2023
Biodistribution, Gene, Drug discovery, High, GenScript Biotech, Research, AAV, Editas Medicine, Messenger, Associate, Cell engineering, Berlin Center, Cell, ISCB Senior Scientist Award, Protein engineering, HSC, UCLA, Synthetic biology, Safety, Vaccine

PISCATAWAY, N.J., July 19, 2023 /PRNewswire-PRWeb/ -- GenScript Biotech Corporation, a world-leading biotech company offering comprehensive solutions in gene, peptide, protein, and antibody research, is pleased to announce the 3rd Annual Gene and Cell Engineering Virtual Summit on July 26, 2023. The event will kick off at 11:00 a.m. Eastern Daylight Time in collaboration with the prominent science networking site, Labroots.

Key Points: 
  • GenScript Biotech's 3rd Annual Gene and Cell Engineering Summit on July 26th, 2023, will gather top scientists to explore advancements in synthetic biology and biotherapeutics.
  • PISCATAWAY, N.J., July 19, 2023 /PRNewswire-PRWeb/ -- GenScript Biotech Corporation , a world-leading biotech company offering comprehensive solutions in gene, peptide, protein, and antibody research, is pleased to announce the 3rd Annual Gene and Cell Engineering Virtual Summit on July 26, 2023.
  • GenScript has cemented its place at the forefront of the gene and cell engineering sector through its extensive services, which include gene synthesis, mRNA synthesis, peptide synthesis, custom antibody generation, and protein engineering.
  • The summit promises to provide a dynamic forum for discussing ground-breaking innovations in gene and cell engineering and fostering collaborations between scientists globally.

MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies

Retrieved on: 
Monday, July 10, 2023
LSE, Partnership, SPL, T-cell lymphoma, Cell engineering, IND, Safety, Pharmaceutical industry, Vittoria

Under the terms of the agreement, Vittoria will obtain non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.

Key Points: 
  • Under the terms of the agreement, Vittoria will obtain non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.
  • In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue.
  • “Through our partnership with Vittoria, MaxCyte has gained an opportunity to further validate and showcase our technology in a real-world setting and expand its footprint in the promising field of CAR-T therapies.
  • By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT™ platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics.

MaxCyte Signs Strategic Platform License with Lyell Immunopharma

Retrieved on: 
Thursday, July 6, 2023
LSE, Lyell, Cell, Patient, SPL, Cell engineering, Vaccine, Pharmaceutical industry

ROCKVILLE, Md., July 06, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced the signing of a strategic platform license (SPL) with Lyell Immunopharma, Inc., a clinical stage T cell reprogramming company.

Key Points: 
  • Lyell Immunopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform in its T cell product candidates targeting solid tumors.
  • ROCKVILLE, Md., July 06, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced the signing of a strategic platform license (SPL) with Lyell Immunopharma, Inc., a clinical stage T cell reprogramming company.
  • Under the terms of the agreement, Lyell Immunopharma obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.
  • In return, MaxCyte is eligible to receive platform licensing fees, clinical milestone payments and sales-based payments.

Leading biotech startup Shiru commercializes the first food ingredient developed using its AI-powered technology platform

Retrieved on: 
Tuesday, June 20, 2023
Database, DNA, Partnership, Food, Genetic engineering, Agriculture, Israel in the Eurovision Song Contest 1993, Intelligence, Medicine, Temperature, Impossible, Protein, Machine learning, Engineering, Artificial intelligence, Biology, AI, Cell engineering, Synthetic biology, Impossible Foods, Fine chemical

After OleoProTM’s successful debut in March at a global food tech conference, Shiru will expand its partnership with Griffith Foods to leverage OleoProTM to bring best-in-class alternative protein products to market.

Key Points: 
  • After OleoProTM’s successful debut in March at a global food tech conference, Shiru will expand its partnership with Griffith Foods to leverage OleoProTM to bring best-in-class alternative protein products to market.
  • ALAMEDA, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Shiru, an AI-powered discovery and development company for novel ingredients, has commercialized the first food ingredient developed using its patented artificial intelligence-powered discovery system.
  • The biotech startup confirmed this week the commercial launch of OleoProTM, a novel, plant protein-based fat ingredient for use in a range of alternative protein food products.
  • Shiru debuted OleoProTM in March at a global food tech conference in a plant-based chicken karaage, developed by Griffith’s corporate venture arm, Nourish Ventures .

GenScript Debuts AmMag™ Quatro to Revolutionize Automated Plasmid Maxi-Prep Purification

Retrieved on: 
Tuesday, June 20, 2023
DNA, Plasmid, Genetic engineering, Workflow, Quatro, Biotechnology, GenScript Biotech, Research, Transfection, Laboratory, Risk, Bacteria, Cell engineering, Vaccine

PISCATAWAY, N.J., June 20, 2023 /PRNewswire/ -- GenScript Biotech Corporation, the world's leading provider of life-science research tools and services, has added the AmMag™ Quatro automated plasmid purification system to its lab and research product line-up. The system streamlines maxi-scale plasmid purification and reduces the manpower and time needed to purify high-quality, transfection-grade plasmid. Since its introduction, AmMag Quatro has been used at the forefront of biotech research, including breakthrough projects such as viral vector development for cell engineering and gene therapy.

Key Points: 
  • PISCATAWAY, N.J., June 20, 2023 /PRNewswire/ -- GenScript Biotech Corporation , the world's leading provider of life-science research tools and services, has added the AmMag™ Quatro automated plasmid purification system to its lab and research product line-up.
  • The system streamlines maxi-scale plasmid purification and reduces the manpower and time needed to purify high-quality, transfection-grade plasmid.
  • However, traditional plasmid purification methods are highly labor-intensive, inefficient, and prone to costly human or process errors.
  • It has exceeded our expectations in terms of time and cost savings, and it has become the standard for our organization's plasmid purification needs."